# Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder

> **NCT05266716** · NA · COMPLETED · sponsor: **Affect Therapeutics, Inc.** · enrollment: 79 (actual)

## Conditions studied

- Methamphetamine Abuse

## Interventions

- **BEHAVIORAL:** Affect Methamphetamine Treatment Program

## Key facts

- **NCT ID:** NCT05266716
- **Lead sponsor:** Affect Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-18
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-01-07
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266716, "Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05266716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*